Linda B. Baughn, PhD
Research Interests:
The proteasome inhibitor Bortezomib is widely used to treat multiple myeloma, relapsed mantle cell lymphoma and is being evaluated in clinical trials for other B cell malignancies. However, due to the development of drug resistance, patients treated with Bortezomib eventually relapse. One of my goals is to understand the basis of Bortezomib resistance and to determine whether the enzyme, activation induced cytidine deaminase contributes to the development of drug resistance.
Selected Publications:
Fessler SP, Rosenberg N and Baughn LB. 2011. SHIP inhibits Abelson Virus Transformation. Journal of Virology, 85:9239-42
Baughn LB, Kalis SL, MacCarthy T, Wei L, Fan M, Bergman A, Scharff MD. 2011. Recombinase mediated cassette exchange as a novel method to study somatic hypermutation in Ramos cells. mBio, 2:5e00186-11
Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S. (2009) CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. Journal of Immunology, 182 (4): 1810-7
Baughn LB*, Di Liberto M*, Wu K, Toogood PL, Louie T, Gottschalk R, Ely S, Niesvizky, R, Cho H, Ely S, Moore MA, and Chen-Kiang S. (2006) A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Research, 66 (15): 7661-7. * Equal contribution
Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane L, Chen-Kiang S. (2005) Mutually exclusive cdk4-cyclin D1 and cdk6-cyclin D2 pairing inactivates Rb and promotes cell cycle dysregulation in multiple myeloma. Cancer Research, 65: 11345-53.
Baughn LB and Rosenberg, N. (2005) Disruption of the shc/grb2 complex during Abelson Virus transformation affects proliferation, but not apoptosis. J of Virol. 79 (4): 2325-34.
Crowder MW, Walsh TR, Banovic L, Pettit M, Spencer J. (1998) Overexpression, purification, and characterization of the cloned metallobeta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob. Agents Chemothera, 42 (4): 921-926.
Crowder MW, Maiti MK, Banovic L, Makaroff CA. (1997) Glyoxalase II from A. thaliana requires Zn (II) for catalytic activity. FEBS Lett., 418 (3): 351-354.
